Malcolm Roberts has worked in R&D within the pharmaceutical industry for over 15 years. He has led numerous drug discovery projects with a focus on Alzheimer’s and Parkinson’s diseases. Most recently, in collaboration with University College London (UCL), Dr. Roberts has led an anti-tau therapeutic antibody project for Alzheimer’s disease from concept through to IND submission. A Phase I human trial for the antibody E2814 is currently being planned. Prior to tau research, he led Eisai’s drug discovery program on LRRK2, a multifunctional protein with a strong genetic association to Parkinson’s disease. He has also undertaken extensive research investigating gamma secretase and mitochondrial mechanisms of cell death in neurodegeneration. Dr. Roberts’ laboratory skills include biochemistry, cell culture, molecular biology and assay development.